Tyrosine kinase involvement in renal arteriolar constrictor responses to angiotensin II

Pamela K Carmines, Rachel W. Fallet, Qi Che, Keiji Fujiwara

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Experiments were performed to test the hypothesis that tyrosine kinase activity contributes to renal arteriolar contractile responses to angiotensin (Ang) II. Rats were subjected to short-term enalaprilat treatment to decrease endogenous Ang II formation before tissue was harvested for experiments with the in vitro blood-perfused juxtamedullary nephron technique. Acute surgical papillectomy was used to avoid the indirect afferent arteriolar effect of Ang II that arises through increased tubuloglomerular feedback sensitivity. Arteriolar lumen diameter responses to 1 and 10 nmol/L Ang II were monitored by videomicroscopic methods before and during treatment with various tyrphostin compounds: 100 μmol/L AG18 (broad-spectrum tyrosine kinase inhibitor), 100 nmol/L AG 1478 (selective epidermal growth factor receptor tyrosine kinase inhibitor), or 100 μmol/L AG9 (inactive analog). Baseline afferent arteriolar lumen diameter averaged 23.5 ± 1.2 μm and was not influenced by any tyrphostin. Ang II (10 nmol/L) decreased afferent diameter by 11.1 ± 1.0 μm under untreated conditions, a response that was not altered by AG9 but significantly blunted by AG18 (34 ± 9% inhibition) or AG1478 (52 ± 8% inhibition). AG18 did not suppress afferent arteriolar contractile responses to membrane depolarization (20 to 55 mmol/L K+ bath). Efferent arteriolar baseline diameter averaged 24.1 ± 0.8 μm and was unaltered by AG 18 or AG1478: however, efferent diameter responses to 10 nmol/L Ang II were diminished 52 ± 10% by AG18 and 51 ± 13% by AG1478. These observations indicate that Ang II signaling in renal afferent and efferent arteriolar vascular smooth muscle is either mediated or modulated by tyrosine kinase activity, including that of the epidermal growth factor receptor tyrosine kinase.

Original languageEnglish (US)
Pages (from-to)569-573
Number of pages5
JournalHypertension
Volume37
Issue number2 II
StatePublished - Mar 19 2001

Fingerprint

Angiotensin II
Protein-Tyrosine Kinases
Kidney
Tyrphostins
Epidermal Growth Factor Receptor
Enalaprilat
Nephrons
Baths
Vascular Smooth Muscle
Membranes
tyrphostin AG 1478
Therapeutics

Keywords

  • Angiotensin II
  • Arterioles
  • Kinase
  • Receptors

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Tyrosine kinase involvement in renal arteriolar constrictor responses to angiotensin II. / Carmines, Pamela K; Fallet, Rachel W.; Che, Qi; Fujiwara, Keiji.

In: Hypertension, Vol. 37, No. 2 II, 19.03.2001, p. 569-573.

Research output: Contribution to journalArticle

Carmines, PK, Fallet, RW, Che, Q & Fujiwara, K 2001, 'Tyrosine kinase involvement in renal arteriolar constrictor responses to angiotensin II', Hypertension, vol. 37, no. 2 II, pp. 569-573.
Carmines, Pamela K ; Fallet, Rachel W. ; Che, Qi ; Fujiwara, Keiji. / Tyrosine kinase involvement in renal arteriolar constrictor responses to angiotensin II. In: Hypertension. 2001 ; Vol. 37, No. 2 II. pp. 569-573.
@article{bac03cc4792f4752ac18b8487d0fa219,
title = "Tyrosine kinase involvement in renal arteriolar constrictor responses to angiotensin II",
abstract = "Experiments were performed to test the hypothesis that tyrosine kinase activity contributes to renal arteriolar contractile responses to angiotensin (Ang) II. Rats were subjected to short-term enalaprilat treatment to decrease endogenous Ang II formation before tissue was harvested for experiments with the in vitro blood-perfused juxtamedullary nephron technique. Acute surgical papillectomy was used to avoid the indirect afferent arteriolar effect of Ang II that arises through increased tubuloglomerular feedback sensitivity. Arteriolar lumen diameter responses to 1 and 10 nmol/L Ang II were monitored by videomicroscopic methods before and during treatment with various tyrphostin compounds: 100 μmol/L AG18 (broad-spectrum tyrosine kinase inhibitor), 100 nmol/L AG 1478 (selective epidermal growth factor receptor tyrosine kinase inhibitor), or 100 μmol/L AG9 (inactive analog). Baseline afferent arteriolar lumen diameter averaged 23.5 ± 1.2 μm and was not influenced by any tyrphostin. Ang II (10 nmol/L) decreased afferent diameter by 11.1 ± 1.0 μm under untreated conditions, a response that was not altered by AG9 but significantly blunted by AG18 (34 ± 9{\%} inhibition) or AG1478 (52 ± 8{\%} inhibition). AG18 did not suppress afferent arteriolar contractile responses to membrane depolarization (20 to 55 mmol/L K+ bath). Efferent arteriolar baseline diameter averaged 24.1 ± 0.8 μm and was unaltered by AG 18 or AG1478: however, efferent diameter responses to 10 nmol/L Ang II were diminished 52 ± 10{\%} by AG18 and 51 ± 13{\%} by AG1478. These observations indicate that Ang II signaling in renal afferent and efferent arteriolar vascular smooth muscle is either mediated or modulated by tyrosine kinase activity, including that of the epidermal growth factor receptor tyrosine kinase.",
keywords = "Angiotensin II, Arterioles, Kinase, Receptors",
author = "Carmines, {Pamela K} and Fallet, {Rachel W.} and Qi Che and Keiji Fujiwara",
year = "2001",
month = "3",
day = "19",
language = "English (US)",
volume = "37",
pages = "569--573",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "2 II",

}

TY - JOUR

T1 - Tyrosine kinase involvement in renal arteriolar constrictor responses to angiotensin II

AU - Carmines, Pamela K

AU - Fallet, Rachel W.

AU - Che, Qi

AU - Fujiwara, Keiji

PY - 2001/3/19

Y1 - 2001/3/19

N2 - Experiments were performed to test the hypothesis that tyrosine kinase activity contributes to renal arteriolar contractile responses to angiotensin (Ang) II. Rats were subjected to short-term enalaprilat treatment to decrease endogenous Ang II formation before tissue was harvested for experiments with the in vitro blood-perfused juxtamedullary nephron technique. Acute surgical papillectomy was used to avoid the indirect afferent arteriolar effect of Ang II that arises through increased tubuloglomerular feedback sensitivity. Arteriolar lumen diameter responses to 1 and 10 nmol/L Ang II were monitored by videomicroscopic methods before and during treatment with various tyrphostin compounds: 100 μmol/L AG18 (broad-spectrum tyrosine kinase inhibitor), 100 nmol/L AG 1478 (selective epidermal growth factor receptor tyrosine kinase inhibitor), or 100 μmol/L AG9 (inactive analog). Baseline afferent arteriolar lumen diameter averaged 23.5 ± 1.2 μm and was not influenced by any tyrphostin. Ang II (10 nmol/L) decreased afferent diameter by 11.1 ± 1.0 μm under untreated conditions, a response that was not altered by AG9 but significantly blunted by AG18 (34 ± 9% inhibition) or AG1478 (52 ± 8% inhibition). AG18 did not suppress afferent arteriolar contractile responses to membrane depolarization (20 to 55 mmol/L K+ bath). Efferent arteriolar baseline diameter averaged 24.1 ± 0.8 μm and was unaltered by AG 18 or AG1478: however, efferent diameter responses to 10 nmol/L Ang II were diminished 52 ± 10% by AG18 and 51 ± 13% by AG1478. These observations indicate that Ang II signaling in renal afferent and efferent arteriolar vascular smooth muscle is either mediated or modulated by tyrosine kinase activity, including that of the epidermal growth factor receptor tyrosine kinase.

AB - Experiments were performed to test the hypothesis that tyrosine kinase activity contributes to renal arteriolar contractile responses to angiotensin (Ang) II. Rats were subjected to short-term enalaprilat treatment to decrease endogenous Ang II formation before tissue was harvested for experiments with the in vitro blood-perfused juxtamedullary nephron technique. Acute surgical papillectomy was used to avoid the indirect afferent arteriolar effect of Ang II that arises through increased tubuloglomerular feedback sensitivity. Arteriolar lumen diameter responses to 1 and 10 nmol/L Ang II were monitored by videomicroscopic methods before and during treatment with various tyrphostin compounds: 100 μmol/L AG18 (broad-spectrum tyrosine kinase inhibitor), 100 nmol/L AG 1478 (selective epidermal growth factor receptor tyrosine kinase inhibitor), or 100 μmol/L AG9 (inactive analog). Baseline afferent arteriolar lumen diameter averaged 23.5 ± 1.2 μm and was not influenced by any tyrphostin. Ang II (10 nmol/L) decreased afferent diameter by 11.1 ± 1.0 μm under untreated conditions, a response that was not altered by AG9 but significantly blunted by AG18 (34 ± 9% inhibition) or AG1478 (52 ± 8% inhibition). AG18 did not suppress afferent arteriolar contractile responses to membrane depolarization (20 to 55 mmol/L K+ bath). Efferent arteriolar baseline diameter averaged 24.1 ± 0.8 μm and was unaltered by AG 18 or AG1478: however, efferent diameter responses to 10 nmol/L Ang II were diminished 52 ± 10% by AG18 and 51 ± 13% by AG1478. These observations indicate that Ang II signaling in renal afferent and efferent arteriolar vascular smooth muscle is either mediated or modulated by tyrosine kinase activity, including that of the epidermal growth factor receptor tyrosine kinase.

KW - Angiotensin II

KW - Arterioles

KW - Kinase

KW - Receptors

UR - http://www.scopus.com/inward/record.url?scp=0035095652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035095652&partnerID=8YFLogxK

M3 - Article

C2 - 11230336

AN - SCOPUS:0035095652

VL - 37

SP - 569

EP - 573

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 2 II

ER -